Nevro Shares Down 3.5% Following Q3 Results
<p><a href='https://financialmodelingprep.com/financial-summary/NVRO'>Nevro Corp. (NYSE:NVRO) </a>shares closed 3.50% lower on Tuesday, following the company’s reported Q3 results, with an EPS of ($0.87), almost in line with the consensus estimate. Quarterly revenues decreased 14.1% year-over-year to $93.2 million, better than the consensus estimate by 2.1%.</p>
<p>The company provided its Q4 outlook, expecting revenue of $94-98 million, below the consensus estimate of $112 million.</p>
<p>Analysts at Oppenheimer provided the following key points on the company:</p>
<p>(1) Soft outlook expected to continue into 1H22,</p>
<p>(2) Logistics of DTC in PDN is unclear, especially the role of endocrinologists in the process,</p>
<p>(3) How growth in PDN will hold up when the CBP market is slowing is unclear,</p>
<p>(4) Company commentary reflecting challenges in an otherwise-flattish market. Commentary on growth returning in 2H22 is bound to raise concerns.</p>

NYSE:NVRO